No study locations reported - 01 Jun `26A Study to Learn How Safe ACT-777991 is and How Well it Works in Adults With Non-segmental Vitiligo

A Study to Learn How Safe ACT-777991 is and How Well it Works in Adults With Non-segmental Vitiligo

Official title: A Phase 2a, Proof of Concept, Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial to Assess the Efficacy and Safety of ACT-777991 in Adults With Non-segmental Vitiligo

Status: Opening soon

Description:

The purpose of this clinical trial is to learn how well ACT-777991 works, how safe it is and how well it is tolerated by adults with non-segmental vitiligo. The main question this clinical trial aims to answer is: • Can ACT-777991 help return color to the skin of the face of adults with non-segmental vitiligo? Researchers will compare ACT-777991 to placebo (a look-alike inactive treatment that contains no medicine) to see if ACT-777991 works to treat non-segmental vitiligo. Trial participants will: • Take the trial intervention (either ACT-777991 or placebo) daily for 24 weeks. • Visit the clinic 7 times for check-up and tests.

Phase: Phase 2.

What is being studied: drugs — ACT-777991, Placebo.

Who can take part: ages 18 Years to 65 Years, 30 participants planned.

Enrollment status: Opening soon. The study started 01 June 2026 and is expected to finish 01 July 2027.

Contact: Clinical Trial Information USA.

Source: ClinicalTrials.gov, NCT07667569 (https://clinicaltrials.gov/study/NCT07667569).

Start date: June 01, 2026

Completion date: July 01, 2027

Organizer: Idorsia Pharmaceuticals Ltd.

Contact: Clinical Trial Information USA

Tel.: +1 856 661 37 21

Email: idorsiaclinicaltrials@idorsia.com

Link: https://clinicaltrials.gov/study/NCT07667569

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference A Study to Learn How Safe ACT-777991 is and How Well it Works in Adults With Non-segmental Vitiligo . By submitting you agree to our Privacy Policy.

FAQOther Questions